Melflufen in combination with dexamethasone induced a 26% overall response rate (ORR) in patients with triple-class refractory multiple myeloma, according to final topline results from the pivotal phase II HORIZON study announced by Oncopeptides AB, the developer of the first-in-class anticancer peptide-drug conjugate.1
Regarding toxicity, grade 3/4 adverse events were mainly hematologic, and the occurrence of nonhematologic AEs was infrequent.
- Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class refractory multiple myeloma patients from the pivotal HORIZON study. Published online March 26, 2020. https://bit.ly/33Oy20T. Accessed March 26, 2020.
- Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019. Published online March 26, 2020. https://bit.ly/2xn7qb8. Accessed March 26, 2020.
... to read the full story